Company & Sponsor Intelligence
Daiichi Sankyo
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials4
Recruiting0
Completed2
Countries1
Therapeutic footprint
out_of_scopepain_neuropathyparkinsonsstroke
Indexed studies
NCT02673866Study to Evaluate the Efficacy and Safety of DS-1971a for the Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)
pain_neuropathy · PHASE2
pain_neuropathy · PHASE2
NCT05203692A Study of a Single Ascending Dose Study of DS-7011a in Healthy Subjects
out_of_scope · United StatesPHASE1
out_of_scope · United StatesPHASE1
NCT00272909Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)
stroke · United StatesPHASE2
stroke · United StatesPHASE2
NCT00623363Preliminary Study of Piclozotan in Patients With Motor Complications Associated With Parkinson's Disease
parkinsons · United StatesPHASE2
parkinsons · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →